Abstract
Non-Hodgkin’s lymphoma (NHL) in childhood was a deadly diagnosis in most cases until the early 1970s. At that point of time, the Berlin-Frankfurt-Muenster study group ran their first NHL study very similar to the BFM treatment for acute lymphoblastic leukemia (ALL). The first study reached an event-free survival of 75% for none-B-NHL but only 34% for B-NHL. So for the next study, the NHL-BFM group developed for B-NHL a new strategy out of two different five-day courses which increased the event-free survival for this patient group up to 70%. Over the next decades, therapy intensity was stratified along prognostic factors to minimize the risk for late effects. Due to that reason cranial radiotherapy was also eliminated for most patients. Nevertheless patients have an increased risk for developing some late effects of their treatment even in the period of long-term survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
